Progress in Nipah Virus (NiV) Vaccine Development

NiV relies on G and F proteins to infect host cells. They are major targets for antiviral drug and vaccine research. Currently, the development of vaccines remains in the preclinical stage. For subunit vaccines, it is found that eukaryotic expression of F proteins induced the production of NiV-neutralising antibodies very well. Pre-incubation of soluble recombinant G protein with sensitive cells inhibits NiV infection. The Peptide Vaccine for NiV is still in the stage of computer simulation analysis. The inhibitory effect is more obvious as the concentration of soluble G protein increases.

Fig.1 Structure of NiV. (Singh, et al., 2019)

NiV Vaccine Development Service at CD BioGlyco

CD BioGlyco aims to facilitate clients in vaccine research. It is mainly the two proteins of NiV that induce the production of neutralizing antibodies: the G and F proteins. Therefore, most vaccines in development target these two proteins. For traditional vaccines, the high lethality of NiV makes the strategy of live attenuated vaccines risky. New vaccines such as live vector vaccines, subunit vaccines, DNA vaccines, and peptide vaccines have become a hot research topic. We provide Subunit Vaccine Development services for NiV.

We take the G and F proteins as the research targets and analyze the sequences of the genes encoding the two proteins comparatively. Afterward, we construct recombinant plasmids and express them solublely using Mammalian Cells. We will determine the optimal induction conditions for the recombinant proteins to enhance the expression rate of the proteins. Our vaccine evaluation system is very well developed. Inflammatory factors, cytokines, coagulation factors, etc., can be tested. Recombinant subunit vaccines may have problems such as low immunogenicity. We also have ways to improve this. We improve the efficacy of the vaccine by adding Adjuvants or optimizing the expression system.

Fig.2 Process of subunit vaccine development. (CD BioGlyco)

Applications

• Our NiV vaccine development services include the recombinant design of F and G proteins, which can assist in establishing an efficient and specific NVD detection method.
• The F and G proteins we produce lay the foundation for subsequent studies on the structure of NiV proteins, invasion mechanisms, and other related research.
• Our recombinant F and G proteins are crucial for anti-NiV monoclonal antibody research.

Highlights of Us

• Our efficient production of G proteins contributes to the development of NiV vaccines.
• Recombinant subunit vaccines we develop have various advantages such as scalable production, relative safety, and high efficiency. They are more targeted and have a simpler composition.
• The mammalian system we use has several advantages. It has a post-transcriptional processing system and a post-translational modification system that enables true secretory expression.

CD BioGlyco is experienced in sugar-related Vaccine Development and provides custom vaccine development solutions. Please feel free to contact us for detailed steps and methods of vaccine development. We will be happy to address any difficulties you may encounter in the vaccine development process.

Reference

1. Singh, R.K.; et al. Nipah virus: epidemiology, pathology, immunobiology, and advances in diagnosis, vaccine designing, and control strategies - a comprehensive review. Vet Q. 2019, 39(1): 26-55.